LGVN

Longeveron Inc. Class A · NASDAQ

Sector Health Technology
Industry Biotechnology
Website longeveron.com
Employees(FY) 19
ISIN US54303L2034

Performance

-16.88%

1W

-63.74%

1M

+141.51%

3M

-29.67%

6M

-5.88%

YTD

-95.79%

1Y

Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Advanced Technical Analysis

Technical Analysis of LGVN 2024-05-10

Overview:

In analyzing the technical indicators for LGVN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions to guide your invest...

See more ...

Recent News & Updates

2024-05-14 04:05
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-05-10 04:05
Longeveron Announces Board of Directors Planned Transitions(Globenewswire)
2024-05-01 20:03
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024(Globenewswire)
2024-04-28 21:00
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV(Accesswire)
2024-04-25 04:05
Longeveron to Present at the Planet MicroCap Showcase(Globenewswire)
2024-04-19 00:13
12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By(Insidermonkey)
2024-04-18 04:05
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering(Globenewswire)
2024-04-16 20:00
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds(Globenewswire)
2024-04-16 01:08
Hedge Fund and Insider Trading News: Ken Griffin, Per Johansson, David Tepper, Michael Platt, Third Point LLC, Millennium Management, Bridgewater Associates, Paloma Partners, Longeveron Inc (LGVN), MongoDB, Inc. (MDB) and More(Insidermonkey)
2024-04-14 20:30
Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC)(Globenewswire)
2024-04-14 20:24
Why Is Longeveron (LGVN) Stock Up 48% Today?(Investorplace)
2024-04-11 05:17
Longeveron Announces Closing of $5.2 Million Public Offering(Globenewswire)
2024-04-08 02:15
Longeveron Announces Pricing of $5.25 Million Public Offering(Globenewswire)
2024-04-07 20:30
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals(Globenewswire)
2024-04-07 19:56
Why Is Longeveron (LGVN) Stock Up 82% Today?(Investorplace)
2024-03-19 04:01
Longeveron Announces 1-for-10 Reverse Stock Split(Globenewswire)
2024-02-27 21:05
With cash runways ending this year, Nicox and Longeveron trim staff and narrow focus(Fiercebiotech)
2024-02-27 20:19
Longeveron Inc. (NASDAQ:LGVN) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-02-27 03:05
Longeveron Reports Year-End 2023 Results and Provides Corporate Update(Globenewswire)
2024-02-21 03:05
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024(Globenewswire)
2024-01-28 19:00
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B(Yahoo Finance)
2023-12-22 03:05
Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules(Globenewswire)
2023-12-20 21:34
UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules(Globenewswire)
2023-12-20 19:00
Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules(Globenewswire)
2023-12-19 19:00
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B in the Treatment of Mild Alzheimer's Disease(Globenewswire)
2023-11-13 19:17
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Wa'el Hashad, CEO of Longeveron Inc.(Globenewswire)
2023-11-10 20:00
Long-term Survival Data from Longeveron's ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association(Globenewswire)
2023-11-10 19:38
Longeveron Inc. (NASDAQ:LGVN) Q3 2023 Earnings Call Transcript(Insidermonkey)
2023-11-09 18:30
Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update(Globenewswire)
2023-11-02 20:00
Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023(Globenewswire)

Page 1 of 4

previousnext